Sagimet Biosciences(SGMT.US)

Last Updated 19:00:00 ET
longbridge loading

Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

Tip Ranks·
US
SGMT
+5.26%
US
FBT
+0.69%
US
IXJ
+0.67%
Tip Ranks·
US
SGMT
+5.26%
US
FBT
+0.69%
US
IXJ
+0.67%

Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target

Tip Ranks·
US
SGMT
+5.26%
US
XLV
+0.69%
US
SBIO
+1.84%
Tip Ranks·
US
SGMT
+5.26%
US
XLV
+0.69%
US
SBIO
+1.84%

Sagimet Biosciences | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
SGMT
+5.26%
Earnings Watch·
US
SGMT
+5.26%

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Market Beat·
US
SGMT
+5.26%
US
BBH
+0.64%
US
FBT
+0.69%
Market Beat·
US
SGMT
+5.26%
US
BBH
+0.64%
US
FBT
+0.69%

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

benzinga_article·
US
SGMT
+5.26%
US
BBH
+0.64%
US
IBB
+0.68%
benzinga_article·
US
SGMT
+5.26%
US
BBH
+0.64%
US
IBB
+0.68%

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga_article·
US
CMPX
+2.12%
US
ADGM
+0.13%
US
SCNI
+4.00%
benzinga_article·
US
CMPX
+2.12%
US
ADGM
+0.13%
US
SCNI
+4.00%

Sagimet Biosciences Jumps 41% After Securing $175M for Phase 3 Acne Trial

Movers Alert·
US
SGMT
+5.26%
US
IBB
+0.68%
US
BIB
+1.41%
Movers Alert·
US
SGMT
+5.26%
US
IBB
+0.68%
US
BIB
+1.41%
© 2026 Longbridge｜Disclaimer